Emerging options and future strategies in immunotherapy for advanced lung squamous-cell carcinoma
Year: 2025
Type: article
Abstract: Advanced-stage lung squamous-cell carcinoma (LUSC) remains a therapeutic challenge. Although immune checkpoint inhibitors (ICIs) have revolutionized LUSC treatment, only a small subset of LUSC patients can achieve durable clinical benefits, underscoring the need for novel strategies. Emerging immunotherapy strategies have demonstrated early evidence of promise for LUSC patients, particularly multi-specific antibodies and fusion proteins, antibody-drug conjugates, adoptive cell therapies, and cancer vaccines. Additionally, advances in multi-omics and artificial intelligence offer potential for precise immunotherapy by deciphering the complex tumor-immune microenvironment and predicting therapeutic responses. The future of LUSC treatment lies in rational multi-target and biological therapies to boost immune cytotoxicity, as well as innovative technologies to refine patient selection. This review highlights the evolving landscape and outlines a roadmap for next-generation immunotherapies in LUSC.
Source: Annals of Oncology
Authors: Y. Wang, R. Rosell, F.R. Hirsch, S. Lu, R. Govindan, K. Park, S. Peters, J.J. Zhang
Institutions: University Health Network, Sheng Jing Hospital, Princess Margaret Cancer Centre, China Medical University, Instituto Oncológico Dr. Rosell, Hospital Universitario Dexeus, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Shanghai Jiao Tong University, Shanghai Chest Hospital, Washington University in St. Louis, Samsung Medical Center, Sungkyunkwan University, Centre Hospitalier Universitaire Vaudois, Hôpital Orthopédique de la Suisse Romande, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W4416410553